Per Lundkvist

List of Publications by Citations

9 papers	330 citations	7 h-index	10 g-index
10 ext. papers	417 ext. citations	5.2 avg, IF	3.19 L-index

#	Paper	IF	Citations
9	Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. *Diabetologia*, **2018**, 61, 1923-1934	10.3	160
8	Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. *Diabetes, Obesity and Metabolism*, **2017**, 19, 49-60	6.7	52
7	Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year. *Diabetes, Obesity and Metabolism*, **2017**, 19, 1276-1288	6.7	37
6	FKBP5 expression in human adipose tissue: potential role in glucose and lipid metabolism, adipogenesis and type 2 diabetes. *Endocrine*, **2018**, 62, 116-128	4	32
5	Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 193-201	5.6	21
4	Early Changes in Adipose Tissue Morphology, Gene Expression, and Metabolism After RYGB in Patients With Obesity and T2D. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 2601-2613	5.6	14
3	A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss. *Diabetes Therapy*, **2018**, 9, 1511-1532	3.6	9
2	Genotype-based recall to study metabolic effects of genetic variation: a pilot study of PPARG Pro12Ala carriers. *Upsala Journal of Medical Sciences*, **2017**, 122, 234-242	2.8	4
1	Role of peroxisome proliferator-activated receptor gamma Pro12Ala polymorphism in human adipose tissue: assessment of adipogenesis and adipocyte glucose and lipid turnover. *Adipocyte*, **2018**, 7, 285-296	3.2	1